麦金
2021-03-18
该公司预计，这种名为aducanumab的药物将在6月7日之前获得批准，这是美国食品和药物管理局规定的日期。
UPDATE 1-Biogen full-year adjusted profit forecast assumes Alzheimer's drug approval<blockquote>更新1-百健(Biogen)全年调整后利润预测假设阿尔茨海默病药物获得批准</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":327850557,"tweetId":"327850557","gmtCreate":1616077537379,"gmtModify":1616077537379,"author":{"id":3508971616244503,"idStr":"3508971616244503","authorId":3508971616244503,"authorIdStr":"3508971616244503","name":"麦金","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>该公司预计，这种名为aducanumab的药物将在6月7日之前获得批准，这是美国食品和药物管理局规定的日期。</p></body></html>","htmlText":"<html><head></head><body><p>该公司预计，这种名为aducanumab的药物将在6月7日之前获得批准，这是美国食品和药物管理局规定的日期。</p></body></html>","text":"该公司预计，这种名为aducanumab的药物将在6月7日之前获得批准，这是美国食品和药物管理局规定的日期。","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/327850557","repostId":2108766986,"repostType":2,"repost":{"id":"2108766986","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1612355204,"share":"https://www.laohu8.com/m/news/2108766986?lang=zh_CN&edition=full","pubTime":"2021-02-03 20:26","market":"us","language":"en","title":"UPDATE 1-Biogen full-year adjusted profit forecast assumes Alzheimer's drug approval<blockquote>更新1-百健(Biogen)全年调整后利润预测假设阿尔茨海默病药物获得批准</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2108766986","media":"Reuters","summary":"(Adds details on forecast, background) Feb 3 (Reuters) - Drugmaker Biogen Inc on Wednesday prov","content":"<p><html><body>(Adds details on forecast, background)</p><p><blockquote><html><body>（添加有关预测、背景的详细信息）</body></html></blockquote></p><p> Feb 3 (Reuters) - Drugmaker Biogen Inc on Wednesday provided a full-year adjusted profit forecast that included sales from its Alzheimer's drug being reviewed by the U.S. drug agency. </p><p><blockquote>路透2月3日-制药商百健(Biogen Inc)周三提供了全年调整后利润预测，其中包括正在接受美国药品管理局审查的阿尔茨海默氏症药物的销售额。</blockquote></p><p> The company expects the drug, aducanumab, will be approved by June 7, the date set by the U.S. Food and Drug Administration. </p><p><blockquote>该公司预计该药物aducanumab将在美国设定的6月7日之前获得批准。食品和药物管理局。</blockquote></p><p> The road to getting a regulatory approval for the drug has been rocky, with Biogen and partner Eisai Co Ltd scrapping two studies in March 2019 and reversing that decision a few months later.</p><p><blockquote>该药物获得监管部门批准的道路一直坎坷，百健(Biogen)和合作伙伴卫材有限公司(Eisai Co Ltd)于2019年3月取消了两项研究，并在几个月后推翻了这一决定。</blockquote></p><p> An expert panel to the FDA had voted \"no\" to three questions related to whether a single successful large trial of aducanumab was enough evidence of the drug's effectiveness given the clear failure of a second large study. </p><p><blockquote>FDA的一个专家小组对三个问题投了反对票，这些问题涉及鉴于第二项大型研究明显失败，一项成功的aducanumab大型试验是否足以证明该药物的有效性。</blockquote></p><p> Biogen expects 2021 adjusted profit of $17 to $18.5 per share. </p><p><blockquote>Biogen预计2021年调整后每股利润为17美元至18.5美元。</blockquote></p><p> (Reporting by Dania Nadeem and Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)</p><p><blockquote>（Dania Nadeem和Manas Mishra班加罗尔报道；Sriraj Kalluvila编辑）</blockquote></p><p>((Dania.Nadeem@thomsonreuters.com;))</p><p><blockquote>（（Dania.Nadeem@thomsonreuters.com；））</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-Biogen full-year adjusted profit forecast assumes Alzheimer's drug approval<blockquote>更新1-百健(Biogen)全年调整后利润预测假设阿尔茨海默病药物获得批准</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-Biogen full-year adjusted profit forecast assumes Alzheimer's drug approval<blockquote>更新1-百健(Biogen)全年调整后利润预测假设阿尔茨海默病药物获得批准</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2021-02-03 20:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>(Adds details on forecast, background)</p><p><blockquote><html><body>（添加有关预测、背景的详细信息）</body></html></blockquote></p><p> Feb 3 (Reuters) - Drugmaker Biogen Inc on Wednesday provided a full-year adjusted profit forecast that included sales from its Alzheimer's drug being reviewed by the U.S. drug agency. </p><p><blockquote>路透2月3日-制药商百健(Biogen Inc)周三提供了全年调整后利润预测，其中包括正在接受美国药品管理局审查的阿尔茨海默氏症药物的销售额。</blockquote></p><p> The company expects the drug, aducanumab, will be approved by June 7, the date set by the U.S. Food and Drug Administration. </p><p><blockquote>该公司预计该药物aducanumab将在美国设定的6月7日之前获得批准。食品和药物管理局。</blockquote></p><p> The road to getting a regulatory approval for the drug has been rocky, with Biogen and partner Eisai Co Ltd scrapping two studies in March 2019 and reversing that decision a few months later.</p><p><blockquote>该药物获得监管部门批准的道路一直坎坷，百健(Biogen)和合作伙伴卫材有限公司(Eisai Co Ltd)于2019年3月取消了两项研究，并在几个月后推翻了这一决定。</blockquote></p><p> An expert panel to the FDA had voted \"no\" to three questions related to whether a single successful large trial of aducanumab was enough evidence of the drug's effectiveness given the clear failure of a second large study. </p><p><blockquote>FDA的一个专家小组对三个问题投了反对票，这些问题涉及鉴于第二项大型研究明显失败，一项成功的aducanumab大型试验是否足以证明该药物的有效性。</blockquote></p><p> Biogen expects 2021 adjusted profit of $17 to $18.5 per share. </p><p><blockquote>Biogen预计2021年调整后每股利润为17美元至18.5美元。</blockquote></p><p> (Reporting by Dania Nadeem and Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)</p><p><blockquote>（Dania Nadeem和Manas Mishra班加罗尔报道；Sriraj Kalluvila编辑）</blockquote></p><p>((Dania.Nadeem@thomsonreuters.com;))</p><p><blockquote>（（Dania.Nadeem@thomsonreuters.com；））</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2108766986","content_text":"(Adds details on forecast, background) Feb 3 (Reuters) - Drugmaker Biogen Inc on Wednesday provided a full-year adjusted profit forecast that included sales from its Alzheimer's drug being reviewed by the U.S. drug agency. The company expects the drug, aducanumab, will be approved by June 7, the date set by the U.S. Food and Drug Administration. The road to getting a regulatory approval for the drug has been rocky, with Biogen and partner Eisai Co Ltd scrapping two studies in March 2019 and reversing that decision a few months later. An expert panel to the FDA had voted \"no\" to three questions related to whether a single successful large trial of aducanumab was enough evidence of the drug's effectiveness given the clear failure of a second large study. Biogen expects 2021 adjusted profit of $17 to $18.5 per share. (Reporting by Dania Nadeem and Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)((Dania.Nadeem@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":630,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":93,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/327850557"}
精彩评论